Emerging PET/CT Imaging Agent Shows Promise for Diagnosing Clear Cell Renal Cell Carcinoma
Findings from a recent multinational phase III trial demonstrated that the investigational agent TLX250-CDx had an 86 percent sensitivity rate for detecting clear cell renal cell carcinoma via positron emission tomography/computed tomography (PET/CT).
The urgency of timely diagnosis is critical for clear cell renal cell carcinoma. Researchers have reported five-year mortality rates that range from 50 to 70 percent but this rate plummets to 10 percent with subsequent metastasis.1 However, the findings from a new multinational phase III trial suggest that an emerging imaging agent may change the standard of care for diagnosing clear cell renal cell carcinoma.
In a recent multicenter prospective study, researchers assessed the use of the imaging agent 89Zr-DFO-girentuximab (TLX250-CDx, Telix Pharmaceuticals) in positron emission tomography/computed tomography (PET/CT) imaging.2 The study cohort consisted of 300 patients who previously had a single indeterminate renal mass (less than or equal to 7 cm in diameter) detected via computed tomography (CT) or magnetic resonance imaging (MRI).
The researchers found that TLX250-CDx had an 86 percent sensitivity rate, an 87 percent specificity rate and a 93 percent positive predictive value for diagnosing clear cell renal cell carcinoma, according to Telix Pharmaceuticals.2
The company noted that TLX250-CDx has a high affinity for carbonic anhydrase IX (CAIX), a tumor-associated antigen reportedly expressed in up to 95 percent of clear cell renal cell carcinoma. The agent, which previously received a breakthrough designation from the Food and Drug Administration (FDA), has significant potential as a non-invasive alternative for detecting and facilitating improved staging of clear cell renal cell carcinoma, according to Francoise Kraeber-Bodere, M.D., Ph.D., head of the Nuclear Medicine Department at the University Hospital of Nantes in France.
“Results from the phase III ZIRCON study of TLX250-CDx should represent a major milestone in the management of small renal lesions and the diagnosis of clear cell renal cell carcinoma,” noted Dr. Kraeber-Bodere. “There is so much potential in optimal targeting of CAIX, paving the way for better staging of this neoplasia and a theragnostic approach.”
In light of the study findings, Telix Pharmaceuticals said it plans to file a Biologics License Application for TLX250-CDx with the FDA. The company added that future research may examine the use of TLX250-CDx in surveillance, surgical staging, and assessment of treatment response for clear cell renal cell carcinoma.
References
1. Padala SA, Kallam A. Clear Cell Renal Carcinoma. StatPearls. StatPearls Publishing; 2022.T
2. Telix announces topline results of ZIRCON phase III kidney cancer imaging study. Cision PR Newswire. Available at: https://www.prnewswire.com/news-releases/telix-announces-positive-topline-results-of-zircon-phase-iii-kidney-cancer-imaging-study-301669685.html . Published November 6, 2022. Accessed November 8, 2022.
Mammography Study Compares False Positives Between AI and Radiologists in DBT Screening
May 8th 2025For DBT breast cancer screening, 47 percent of radiologist-only flagged false positives involved mass presentations whereas 40 percent of AI-only flagged false positive cases involved benign calcifications, according to research presented at the recent American Roentgen Ray Society (ARRS) conference.
